BioPharm America™ 2017: Platelet BioGenesis generating platelets on demand

Platelets are the bandaids of the bloodstream. Every year more than two million people in the US receive platelet transfusions as part of cancer treatment, transplants and surgery. Unfortunately, platelets are at high risk of bacterial or viral contamination, and have a very short shelf life. We spoke to Sven Karlsson of Platelet BioGenesis, an exciting company and winner of the BioPharm America startup competition, that has developed a ex vivo system for generating immune compatible platelets on demand. […]

Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors

Siamab Therapeutics, Inc. and Boehringer Ingelheim announced today that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens (TACAs). Read more >>